OR WAIT 15 SECS
August 24, 2016
The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, according to business intelligence firm GBI Research.
The company’s latest report states that although this growth is largely attributable to a large increase in the incidence of type 2 diabetes mellitus (T2DM) and obesity, a number of pipeline T2DM therapeutics are anticipated to be significant contributors to market growth over the forecast period, with some even expected to reach blockbuster status.
Recent approvals and pipeline products that are expected to be key players during the forecast period include Novo Nordisk's Tresiba (insulin degludec) and NN-9535 (semaglutide). Although current top-selling drugs such as Januvia, Novolog and Invokana are expected to remain dominant within the disease cluster, four of the anticipated top 10 best-selling drugs of 2022 will be new to market, the report states.